Suppr超能文献

在复发滤泡性淋巴瘤中,将减低强度异基因干细胞移植和自体干细胞移植作为首次移植策略时的结果:来自欧洲血液与骨髓移植协会淋巴瘤工作组的分析

The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.

作者信息

Robinson S P, Canals C, Luang J J, Tilly H, Crawley C, Cahn J Y, Pohlreich D, Le Gouill S, Gilleece M, Milpied N, Attal M, Biron P, Maury S, Rambaldi A, Maertens J, Capria S, Colombat P, Montoto S, Sureda A

机构信息

BMT Unit, Bristol Children's Hospital, Bristol, UK.

出版信息

Bone Marrow Transplant. 2013 Nov;48(11):1409-14. doi: 10.1038/bmt.2013.83. Epub 2013 Jun 17.

Abstract

Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first transplant in this setting. We conducted a retrospective comparison of 726 patients who underwent an auto-SCT and 149 who underwent a RIST as a first transplant procedure for relapsed FL as reported to the Lymphoma Working Party of the European Bone Marrow Transplant. The non-relapse mortality (NRM) was significantly worse for patients undergoing a RIST (relative risk (RR) 4.0, P<0.001). The 1-year NRM was 15% for those undergoing a RIST compared with 3% for those undergoing an auto-SCT. Disease relapse or progression were significantly worse for those receiving an auto-SCT (RR 3.1, P<0.001). Patients undergoing a RIST had a 5-year relapse rate of 20% compared with 47% for those undergoing an auto-SCT. The PFS at 5 years was 57% for patients receiving a RIST compared with 48% for those receiving an auto-SCT. There was no significant difference in OS between the two groups. RIST is associated with a higher NRM and lower relapse rate in patients with relapsed FL.

摘要

自体造血干细胞移植(auto-SCT)和减低强度异基因造血干细胞移植(RIST)均用于复发性滤泡性淋巴瘤(FL)的治疗。我们分析了这两种移植程序在此种情况下作为首次移植时的治疗结果。我们对726例行auto-SCT的患者和149例行RIST作为复发性FL首次移植程序的患者进行了回顾性比较,这些数据已上报给欧洲骨髓移植淋巴瘤工作组。接受RIST的患者非复发死亡率(NRM)明显更高(相对风险(RR)4.0,P<0.001)。接受RIST的患者1年NRM为15%,而接受auto-SCT的患者为3%。接受auto-SCT的患者疾病复发或进展情况明显更差(RR 3.1,P<0.001)。接受RIST的患者5年复发率为20%,而接受auto-SCT的患者为47%。接受RIST的患者5年无进展生存期(PFS)为57%,接受auto-SCT的患者为48%。两组总生存期(OS)无显著差异。RIST与复发性FL患者更高的NRM和更低的复发率相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验